Login to Your Account

Isis-CRPRx Yanked in RA, Phase II Continues in AF

By Marie Powers
Staff Writer

Tuesday, August 6, 2013
Shares of Isis Pharmaceuticals Inc. took little notice Monday of the company's decision to pull the plug on mid-stage candidate ISIS-CRPRx in rheumatoid arthritis (RA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription